Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Jordan

Showing results (611-620 of 682) with videos related to

Pageof 69
Sort By:
Genome Biology|March 4, 2022
Enhanced protein isoform characterization through long-read proteogenomicsRachel M Miller, Ben T Jordan, Madison M Mehlferber, et al.
Diabetes|May 17, 2019
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)Justin M Gregory, T Jordan Smith, James C Slaughter, et al.
Oncotarget|March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaAlisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
American Journal of Human Genetics|October 30, 1998
Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomalyA J Mears, T Jordan, F Mirzayans, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2019
Factors Associated with Supportive Care Service Use Among California Alzheimer's Disease Patients and Their CaregiversLori A Newkirk, Virginia L Dao, Joshua T Jordan, et al.
Journal of Proteome Research|August 18, 2018
An Integrated, High-Throughput Strategy for Multiomic Systems Level AnalysisDanielle B Gutierrez, Randi L Gant-Branum, Carrie E Romer, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
Journal of the American College of Radiology : JACR|May 23, 2025
ACR Appropriateness Criteria® Brain Tumors, Jana Ivanidze, Robert Y Shih, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Pageof 69

Showing results (611-620 of 682) with videos related to

Sort By:
Pageof 69
Genome Biology|March 4, 2022
Enhanced protein isoform characterization through long-read proteogenomicsRachel M Miller, Ben T Jordan, Madison M Mehlferber, et al.
Diabetes|May 17, 2019
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)Justin M Gregory, T Jordan Smith, James C Slaughter, et al.
Oncotarget|March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaAlisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
American Journal of Human Genetics|October 30, 1998
Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomalyA J Mears, T Jordan, F Mirzayans, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2019
Factors Associated with Supportive Care Service Use Among California Alzheimer's Disease Patients and Their CaregiversLori A Newkirk, Virginia L Dao, Joshua T Jordan, et al.
Journal of Proteome Research|August 18, 2018
An Integrated, High-Throughput Strategy for Multiomic Systems Level AnalysisDanielle B Gutierrez, Randi L Gant-Branum, Carrie E Romer, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
Journal of the American College of Radiology : JACR|May 23, 2025
ACR Appropriateness Criteria® Brain Tumors, Jana Ivanidze, Robert Y Shih, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Pageof 69